News for Aptevo Therapeutics Inc. (APVO)

SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing nov

Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo's expansion from hematologic to solid tumorsNew candidate APVO45

Aptevo Therapeutics (APVO) successfully raises $8 million through an at-the-market offering. The offering includes approximately 2.47 million shares wit

Aptevo Therapeutics (APVO) has introduced APVO455, a new preclinical candidate, to its expanding lineup of CD3-directed molecules. This addition is part of a st

U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Friday. Shares of Smith & Wesson Brands Inc SWBI fell sharply in pre-ma...

Shares of Cheetah Mobile Inc. CMCM rose sharply in pre-market trading following first-quarter results. Cheetah Mobile posted a quarterly loss of 11 cents per s...

U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 0.2% on Wednesday. The Dow traded up 0.26% to 42,324.65 while the NASDAQ r...

SEATTLE, WA / ACCESS Newswire / June 18, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immun

85% remission rate observed in evaluable frontline AML patientsMipletamig combination enables rare pathway to transplant in a previously ineligible unfit patien

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.36% to 42,366.99 while ...

Aptevo Therapeutics (APVO) experienced a trading halt with an announcement expected soon. Investors await the forthcoming news, which could potentially impact t

SEATTLE, WA / ACCESS Newswire / May 22, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that it will conduct a revers

Aptevo Therapeutics, under the ticker (APVO), will undergo a reverse stock split, consolidating its common shares in a 1-for-20 ratio. This adjustment is set to

Aptevo Therapeutics (APVO) announces a 1-for-20 reverse stock split effective May 23, 2025. The measure is part of a strategy to maintain Nasdaq Capital

9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trialsMipletamig triplet combination continues to outperform stan

Aptevo Therapeutics (APVO) is celebrating significant progress in its RAINIER trial, highlighting mipletamig as a promising candidate in the treatment of acute

Applied Materials (AMAT) to announce fiscal Q2 2025 earnings on May 15, 2025. Aptevo Therapeutics (APVO) participates in two major conferences in March

Evogene (EVGN), a computational biology company, is experiencing a notable 3,980% surge in investor attention, according to recent data. This surge coincides wi

SEATTLE, WA / ACCESS Newswire / April 22, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focu